Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis-Reference-Cited by-同舟云学术

Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis

Published:2020-11 Issue:11 Volume:140 Page:2294-2298.e6
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

García-Martínez Patricia^ORCID,Collado-Díaz Víctor^ORCID,Mateu-Puchades Almudena^ORCID,Villarroel-Vicente Carlos^ORCID,Rovira-Llopis Susana^ORCID,Blas-García Ana^ORCID,Álvarez Ángeles^ORCID,Esplugues Juan Vicente^ORCID,Andújar Isabel^ORCID

Funder

Ministerio de Ciencia, Innovación y Universidades

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference26 articles.

1. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review;Armstrong;Curr Pharm Des,2014

2. From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies;Hugh;J Am Acad Dermatol,2014

3. Thrombosis and platelets: an update;Koupenova;Eur Heart J,2017

4. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice;Lee;Arterioscler Thromb Vasc Biol,1999

5. Attributable risk estimate of severe psoriasis on major cardiovascular events;Mehta;Am J Med,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics;Pharmaceuticals;2022-09-03

2. Association of Psoriasis With Incident Venous Thromboembolism and Peripheral Vascular Disease;JAMA Dermatology;2022-01-01

3. Detailed Long-term Dynamics of Neutrophil-to-Lymphocyte Ratio under Biologic Treatment Reveals Differential Effects of Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists;Acta Dermato Venereologica;2021

4. Evaluation of Psoriasis Area and Severity Index as a Proxy for Biomarkers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles;Acta Dermato Venereologica;2021